EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeit

Guidelines From the French‐Speaking Society for Histocompatibility and Immunogenetics ( SFHI ) for Harmonisation of HLA Genotyping in Autoimmune Diseases, Drug Hypersensitivity and Pharmacogenetics

Virginie Renac iD, Virginie Moalic, Guillaume Dautin, Mathilde Cherel, Bernard Mercier, Alexandre Walencik, Jacques Cohen, Fabienne Farce, Barbara Proust iD, Rangolie Kaveri, Camille Humeau, Christophe Picard und 12 weitere

HLA · 2025

DOI: 10.1111/tan.70442 ↗

Kurz gefasst

Leitlinie in der Zeitschrift HLA, 2025. Verfasst von Virginie Renac und 23 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire Histocompatibilité-Immunogénétique, Immunologie leuco-plaquettaire, Etablissement Français du Sang (EFS)-Bretagne, Rennes, France. Hauptthemen laut MEDLINE: Autoimmune Diseases, Pharmacogenetics, Drug Hypersensitivity, HLA Antigens. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 142 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HLA molecules play a central role in the adaptive immune response. Their high polymorphism influences individual susceptibility to various autoimmune diseases and certain drug‐induced hypersensitivities. In France, HLA genotyping is classified as a medical genetics procedure and is strictly regulated. The Société Francophone d'Histocompatibilité et d'Immunogénétique ( SFHI ) has established national guidelines outlining clinically validated indications, required resolution levels and interpretation criteria based on robust data. These guidelines are particularly relevant for common clinical contexts, including autoimmune diseases and pharmacogenetic testing. Well‐established associations include HLA‐DQB1*02 / DQA1*05 (DQ2) and HLA‐DQB1*03:02 / DQA1*05 (DQ8) with celiac disease, HLA‐B*27 with spondyloarthritis, HLA‐DQB1*06:02 with type 1 narcolepsy, HLA‐A*29 with Birdshot chorioretinopathy and several pharmacogenetic risk alleles such as HLA‐B*57:01 (abacavir), HLA‐B*15:02 and HLA‐A*31:01 (carbamazepine) and HLA‐B*58:01 (allopurinol). In immunotherapy, the efficacy of tebentafusp has been shown to depend on HLA‐A*02:01 positivity. HLA alleles must be interpreted as relative risk factors, not absolute predictors. Critical analysis of HLA‐related scientific literature requires consideration of the genotyping technique, typing resolution, allele frequencies within the studied population and environmental factors. High‐resolution typing is essential in pharmacogenetics and recommended in selected autoimmune disorders. Interpretation should be conducted by qualified medical biologists, integrating clinical context, allelic diversity and recent technological advances, particularly next‐generation sequencing. HLA genotyping represents a valuable tool in diagnosis and risk assessment, with increasing importance in the era of personalised medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesPharmacogeneticsDrug HypersensitivityHLA AntigensHistocompatibility TestingHumansGenotypeFranceAllelesImmunogeneticsGenetic Predisposition to Disease

Stichwörter der Autor:innen

HLAautoimmune diseasebirdshotceliac diseasedrug hypersensitivityfoetal and neonatal alloimmune thrombocytopenianarcolepsyspondyloarthritistebentafuspuveitis

Substanzen

HLA Antigens

Autor:innen und Institutionen

  • Laboratoire Histocompatibilité-Immunogénétique, Immunologie leuco-plaquettaire, Etablissement Français du Sang (EFS)-Bretagne, Rennes, France.
  • Unité d'histocompatibilité, service de génétique médicale et de biologie de la reproduction, CHRU de Brest, CHU Morvan, Brest, France.
  • Laboratoire d'immunohématologie et d'immunogénétique, EFS-Bourgogne/Franche-Comté, Dijon, France.
  • Laboratoire d'Immunologie et Immunogénétique, EFS-Centre Atlantique Pays de Loire, EFS Centre Pays de la Loire, Nantes, France.
  • Laboratoire d'Immunologie, CHU de Reims, Hôpital Robert Debré, Reims, France.
  • Université de Reims Champagne Ardenne URCA, Reims, France.

ORCID-Profile: Virginie Renac, Barbara Proust, Béatrice Pedron, Vincent Elsermans, Dominique Masson

Zitieren

APA

Renac, V., Moalic, V., Dautin, G., Cherel, M., Mercier, B., Walencik, A., Cohen, J., Farce, F., Proust, B., Kaveri, R., Humeau, C., Picard, C., Pedron, B., Dubois, V., Taupin, J. L., Elsermans, V., Top-Raymond, I., Ferrari-Lacraz, S., Barocas, A., …, & Congy-Jolivet, N. (2025). Guidelines From the French‐Speaking Society for Histocompatibility and Immunogenetics ( SFHI ) for Harmonisation of HLA Genotyping in Autoimmune Diseases, Drug Hypersensitivity and Pharmacogenetics. HLA. https://doi.org/10.1111/tan.70442

Vancouver

Renac V, Moalic V, Dautin G, Cherel M, Mercier B, Walencik A, et al. Guidelines From the French‐Speaking Society for Histocompatibility and Immunogenetics ( SFHI ) for Harmonisation of HLA Genotyping in Autoimmune Diseases, Drug Hypersensitivity and Pharmacogenetics. HLA. 2025. doi:10.1111/tan.70442

BibTeX
@article{Renac2025,
  author = {Renac, Virginie and Moalic, Virginie and Dautin, Guillaume and Cherel, Mathilde and Mercier, Bernard and Walencik, Alexandre and Cohen, Jacques and Farce, Fabienne and Proust, Barbara and Kaveri, Rangolie and Humeau, Camille and Picard, Christophe and Pedron, Béatrice and Dubois, Valérie and Taupin, Jean-Luc and Elsermans, Vincent and Top-Raymond, Isabelle and Ferrari-Lacraz, Sylvie and Barocas, Antoine and Masson, Dominique and Essaydi, Arnaud and Guidicelli, Gwendaline and Ralazamahaleo, Mamy and Congy-Jolivet, Nicolas},
  title = {Guidelines From the French‐Speaking Society for Histocompatibility and Immunogenetics ( SFHI ) for Harmonisation of HLA Genotyping in Autoimmune Diseases, Drug Hypersensitivity and Pharmacogenetics},
  journal = {HLA},
  year = {2025},
  doi = {10.1111/tan.70442}
}
Kostenlos starten →